

Final Appraisal Recommendation

Advice No: 3313 – November 2013

**Saxagliptin (Onglyza®)
2.5 mg and 5 mg film-coated tablets**

Limited submission by AstraZeneca UK Ltd

Recommendation of AWMMSG

Saxagliptin (Onglyza®) is recommended as an option for use within NHS Wales for the treatment of adult patients aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control as triple oral therapy in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Additional note:

- Please refer to the Summary of Product Characteristics for the full licensed indication.

In reaching the above recommendation AWMMSG has taken account of the appraisal documentation prepared by the AWMMSG Secretariat (reference number 1975), which includes the AWMMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue:	AstraZeneca UK Ltd/Bristol-Myers Squibb Pharmaceuticals Ltd
Date of first issue	November 2013
Last reviewed	January 2017

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 3313:
Saxagliptin (Onglyza®) 2.5 mg and 5 mg film-coated tablets. November 2013.